- Deep brain stimulation (DBS) of the ventral capsule/ventral striatum (VC/VS) is a promising neurotherapeutic approach for severe and refractory cases of obsessive-compulsive disorder (OCD). Successful VC/VS-DBS treatment alters function in frontostriatal pathways important for the etiopathogenesis of OCD [1–3]. Monitoring changes in frontostriatal functioning resulting from active DBS can reveal signatures of DBS engagement with disease-relevant pathways [1,4]. In particular, modulation of the dorsal-medial prefrontal cortex (dmPFC) seems to be crucial for therapeutic success: symptomatic OCD patients demonstrate hyperconnectivity between the VC/VS and dmPFC, which is normalized following successful VC/VS-DBS [1,5,6].
- High frequency Deep brain stimulation (DBS) targeting motor thalamus is an effective therapy for essential tremor (ET). However, conventional continuous stimulation may deliver unnecessary current to the brain since tremor mainly affects voluntary movements and sustained postures in ET.
- Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL), motor, and non-motor symptoms (NMS) in Parkinson's disease (PD). Few studies have investigated the influence of the location of neurostimulation on NMS.
- Subthalamic nucleus (STN) deep brain stimulation (DBS) improves quality of life (QoL), motor, and non-motor symptoms (NMS) in advanced Parkinson's disease (PD). However, considerable inter-individual variability has been observed for QoL outcome.
- Subthalamic nucleus (STN) deep brain stimulation (DBS) is well established for the symptomatic treatment of Parkinson's disease (PD) improving motor symptoms, activities of daily living (ADL), and quality of life (QoL) [1–3]. Non-motor symptoms (NMS) play a crucial role for QoL in patients with PD [4,5]. Long-term effects of DBS on neuropsychological [6,7] and neuropsychiatric symptoms [8,9] have been studied. However, these symptoms contribute only to a part of NMS in patients with PD. Previously published studies on a wider range of NMS have methodological limitations due to a lack of objective clinician-based , patient-based [11,12] or any validated assessment at all , and small cohort sizes of only 10 [13,14] or 11 subjects followed up on 6 month .